Sun Pharma

Sun Pharma up 12% in 4 days, nears 52-week high; analysts see more upside?

Supported by the Sun Pharma's proven record of strong cash flows, analysts remain confident in gradual deleveraging over time.

Sun Pharma bets on Organon front-end to drive global growth, efficiencies

Sun Pharma sees its Organon acquisition as a platform to expand globally, boost in-licensing, and improve long-term efficiencies through a stronger commercial front-end

Best of BS Opinion: India's FTA with New Zealand shows agile deal-making

From India's FTA strategy and Sun Pharma's global ambitions to LPG shortages, West Asia risks and Asean ties, here are the key insights from today's Opinion page

Scale and efficiency: Organon's acquisition will benefit Sun Pharma

Organon's portfolio includes over 70 products across women's health and biosimilars

Sun Pharma's $11.75 bn Organon bet: Global pharma leap or balance risk?

Sun Pharma's $11.75 billion Organon deal could boost its global scale and biosimilars reach, but investors are closely watching debt levels, execution risks and long-term returns

Sun Pharmaceutical acquires US-based Organon in $11.75 billion deal

Combined entity to have revenue of $12.4 billion; enters biosimilars big league

Lack of growth visibility at Organon could cap Sun Pharma's gains

Sun Pharma's Organon deal lifts stock, but growth concerns and high debt at the acquired firm may cap upside despite synergy potential

Sun Pharma, Dr Reddy's Labs, Onesource: Nifty Pharma rallies 3%; details

Among others, Sun Pharma was the top gainer up over 7 per cent, followed by Gland Pharma, Alkem Laboratories, Zydus Lifesciences and Wockhardt up over 2 per cent

Sun Pharma rallies 6%, top gainer among Sensex stocks; here's why

Sun Pharma to acquire all outstanding shares of Organon for $14.00 per share in an all cash transaction with an enterprise valuation of $11.75 billion.

Sun Pharma to acquire US drugmaker Organon in $11.75 billion all-cash deal

April 26 (Reuters) - India's Sun Pharmaceutical Industries ​will uy Organon & ​Co in an all-cash ‌deal, valuing the U.S. drugmaker at about $11.75 billion including ebt, the companies said on Sunday.

Nifty Pharma index soars 3%; Dr Reddy's, Piramal Pharma rally up to 9%

Glenmark Pharma, Cipla, Wockhardt, Mankind Pharma, Lupin, Zydus Life, Laurus, Ipca Labs, Divis Labs, Strides Pharma and Onesource were up in the range of 3% to 6%.

Pharma cos brace for soft Q4; US drag persists; domestic growth cushions

Pharma sector may see a 7 per cent Y-o-Y growth in reported sales and a 1 per cent increase in Ebitda, led by steady ex-gRevlimid US sales, healthy domestic growth, and favourable forex movements

Nifty Healthcare below 100-WMA, down 8% from its peak; what charts say?

Amol Athawale of Kotak Securities believes that the short-term outlook for Nifty Healthcare remains uncertain and sentiment may turn negative in case the index falls below 13,500 levels.

10 pharma firms launch semaglutide in India; Nomura sees ₹12k-cr mkt

Companies including Dr. Reddy's Laboratories, Sun Pharma, Zydus Lifesciences, Natco Pharma, Alkem Laboratories, and Torrent Pharmaceuticals have developed their own formulations

Sun Pharma, Dr Reddy's, Glenmark launch generic semaglutide in India

Indian pharma majors Sun Pharma, Dr Reddy's and Glenmark on Saturday announced the launch of their generic versions of semaglutide injection used for diabetes and weight management following the molecule behind products like Ozempic and Wegovy going off patent in India. The prices of the generic versions of semaglutide injection are considerably lower than the prices of the innovator, Novo Nordisk. Sun Pharmaceutical Industries launched its semaglutide injection under the brand names Noveltreat and Sematrinity in India, in all strengths. Noveltreat is indicated for chronic weight management in adults as an adjunct to a reduced calorie diet and increased physical activity and is available in five dose strengths -- 0.25 mg/0.5 ml, 0.5 mg/0.5 ml, 1 mg/0.5 ml, 1.7 mg/0.75 ml, and 2.4 mg/0.75 ml, Sun Pharma said in a statement. Sematrinity is indicated for treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise and is available in t

Stocks to Watch today, March 17: RIL, Tata Motors, Sun Pharma, RVNL, GMDC

Stocks to Watch today, March 17: Reliance Industries, Tata Motors, Sun Pharma, RVNL, GMDC, RailTel, and Sagar Cements are among the top stocks to watch today

Nifty Pharma index hits 52-week high; Ipca, Aurobindo rally up to 4%

In the past one month, the Nifty Pharma index has rallied 4.5 per cent, as against 7.8 per cent decline in the benchmark Nifty 50.

Sun Pharma up 5% in 1 week, nears 52-week high; what's driving this stock?

Sun Pharma is transitioning its US business from low-margin generics to high-value specialty and innovative therapies.

Sun Pharma, Hindustan Aeronautics top stock picks for today; check targets

Sun Pharma and Hindustan Aeronautics are among the top stock picks by Rajesh Bhosale of Angel One

Nifty Pharma index soars 7% thus far in February; nears 52-week high

Thus far in the month of February 2026, Laurus Labs surged 13%, while Sun Pharmaceutical Industries and Torrent Pharmaceuticals soared 11% each.